• Explore /
  • Poster
  • / Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).

Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).

Abstract Poster

Authors

Meletios Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens, Athens, Greece

Meletios A. Dimopoulos , A. Keith Stewart , S. Vincent Rajkumar , Tamás Masszi , Albert Oriol , Roman Hajek , Laura Rosinol , David Samuel DiCapua Siegel , Georgi Mihaylov , Vesselina Goranova-Marinova , Peter Rajnics , Aleksandr Suvorov , Ruben Niesvizky , Andrzej J. Jakubowiak , Jesus F. San Miguel , Heinz Ludwig , Naseem J. Zojwalla , Philippe Moreau , Antonio Palumbo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01080391

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8525)

DOI

10.1200/jco.2015.33.15_suppl.8525

Abstract #

8525

Poster Bd #

342

Abstract Disclosures

Similar Posters

First Author: Heinz Ludwig

First Author: P. Moreau

First Author: Noa Biran

First Author: Andrew Jenho Yee